Table 1 The association between PDCD10 expression and clinicopathological characteristics of HCC patients in training and validation cohort.

Clinicopathological Variables	Training Cohort				Validation Cohort
	n	PDCD10 Expression		P Value	n	PDCD10 Expression		P Value
		Low	High			Low	High
Gender
Female	42	17	25		34	12	22
Male	118	39	79	0.386	106	33	73	0.651
Age (years)
<60	102	41	61		85	24	61
≥60	58	15	43	0.068	55	21	34	0.218
HBsAg
Negative	24	6	18		23	10	13
Positive	136	50	86	0.265	117	35	82	0.203
Liver cirrhosis
Absence	48	16	32		40	16	24
Presence	112	40	72	0.772	100	29	71	0.208
AFP (ng/L)
<20	66	26	40		52	19	33
≥20	94	30	64	0.329	88	26	62	0.392
Child-Pugh
A	120	45	75		96	28	68
B	40	11	29	0.251	44	17	27	0.265
Tumour number
Solitary	68	32	36		64	26	38
Multiple	92	24	68	0.006	76	19	57	0.049
Tumor size
≤5 cm	51	24	27		52	24	28
>5 cm	109	32	77	0.029	88	21	67	0.006
Microvascular invasion
Absence	87	40	47		82	33	49
Presence	73	16	57	0.001	58	12	46	0.015
Capsular formation
Absence	86	24	62		65	17	48
Presence	74	32	42	0.043	75	28	47	0.158
Edmondson-Steiner grade
I–II	86	38	48		71	31	40
III–IV	74	18	56	0.009	69	14	55	0.003
TNM stage
I	65	33	32		58	26	32
II–III	95	23	72	0.001	82	19	63	0.007
BCLC stage
0–A	70	32	38		64	28	36
B–C	90	24	66	0.012	76	17	59	0.007

AFP alpha-fetoprotein, HBsAg hepatitis B surface antigen, TNM tumor node metastasis, BCLC Barcelona Clinic Liver Cancer.
Bold values identify statistical significance (p < 0.05).

Quick links

Search